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Abstract
Introduction: Pulmonary alveolar proteinosis (PAP) is a rare disease in the field of pulmonary medicine. The efficacy of whole-lung 
lavage (WLL) as the treatment of PAP had never been evaluated in the Iranian population. Therefore, there is a real need to inve-
stigate the characteristics of PAP and also to evaluate the efficacy of WLL in this rare disease. The study aimed to investigate 
demographic features, clinical presentation and treatment outcomes of the disease in Iranian PAP patients.
Material and methods: Data of 45 patients with definite diagnosis of PAP, who had regular follow-ups from March 2004 to March 
2015 at an Iranian referral respiratory hospital, were collected. Whole-lung lavages (WLL) efficacy was assessed by comparing 
spirometric, arterial blood gas parameters and six-minute walk test (6MWT) results before and after all lavages.
Results: Mean age at diagnosis of disease was 30.33 ± 14.56 years. Four patients (8.8%) reported non-massive hemoptysis and three 
subjects (6.6%) had concomitant pulmonary tuberculosis. In 71.1% of cases, transbronchial lung biopsy and bronchoalveolar lavage were 
sufficient for diagnosis. Spirometric results and arterial blood gas parameters and 6MWD improved significantly after all the lavages. Four 
patients (8.8%) died because of respiratory failure. The only variable capable of predicting treatment failure was the history of hemoptysis.
Conclusion: The study revealed sufficiency of WLL as the PAP patients’ treatment. Also hemoptysis was found to be the inde-
pendent factor that can predict treatment failure.
Key words: bronchoalveolar lavage (D018893), pulmonary alveolar proteinosis (D011649), whole-lung lavage
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Introduction
Pulmonary alveolar proteinosis (PAP), which 
was first described by Rosen et al., in 1958 [1], is 
a rare and complex disorder caused by the exces-
sive accumulation of lipoproteins within alveolar 
spaces [2]. Basing on pathological aspect, the 
disease is divided into the three following forms: 
“congenital PAP” — with prevalence of 2% of total 
cases, “secondary PAP” — with prevalence of less 
than 10% of all cases, and “idiopathic or acquired 
PAP” — constituting 90% of total cases [2, 3]. 
Congenital PAP is the result of genetic mutation 
in surfactant protein, granulocyte macrophage 
colony-stimulating factor (GM-CSF) receptor or 
ATP-Binding Cassette A3 (ABCA3) [4]. Secondary 
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PAP occurs due to the functional impairment or 
reduction in the number of alveolar macrophages 
being exposed to toxic substances, infections, he-
matologic malignancies and allogeneic stem cell 
transplantation [2, 5]. IPAP, which is also called 
“acquired PAP”, occurs as an autoimmune disease 
with neutralizing antibody of immunoglobulin G 
isotype against GM-CSF [6].
Whole-lung lavage (WLL), which is known as 
the gold standard treatment [7–12] for PAP, was 
used for the first time among Iranian PAP patients 
in the present study. Since 1958, more than 500 
cases of PAP have been reported worldwide [1]. 
Western and Asian countries have published 
reports including data on epidemiology, clinical 
features and treatment outcomes of PAP patients 
[3, 7, 13–16]. One of the largest studies to date is 
a meta-analysis by Seymur et al. reporting on 410 
patients from 241 publications [3]. Another one is 
the largest single center cohort study on PAP which 
was conducted by Bonella et al. [13], and which 
described epidemiologic and different characteri-
stics of PAP patients in Germany. Inoue et al. [15] 
released data on features of 166 Japanese patients 
with PAP [15], furthermore, Xu et al. [14], revie-
wed clinical qualities of 241 patients over time, 
and Byun et al. [17], reviewed features of IPAP in 
the Korean population. Nevertheless, reports on 
characteristics of the disease in Middle East are 
limited. Accordingly, the study by Ben-Dov et al. is 
one of the reports on PAP patients in Middle East 
[18], on the other hand, one brief paper by Parsa et 
al. [19], and two case reports concerning Iranian 
patients by Radpay et al. [20, 21] are available as 
well. WLL had never been used as the treatment 
in Iranian PAP patients before the present study.
In this research, it was decided to describe 
demographic, epidemiological and clinical featu-
res, as well as treatment outcomes of Iranian PAP 
patients during eleven years. 
Material and methods 
Study design 
The study was conducted as a retrospective 
cross-sectional study at the Iranian referral respi-
ratory hospital. Forty-five PAP patients (21 fema-
les and 24 males), i.e. 42 cases from the “adult 
group” and three cases under 14 years of age from 
the “pediatric group” were included in the study 
on the basis of definitive diagnosis of PAP after 
bronchoalveolar lavage (BAL) or transbronchial 
lung biopsy (TBLB) between March 2004 and 
March 2015. Mean age ± SD at diagnosis was 
30.33 ± 14.56 years. 
The patients were contacted by phone in 
order to ascertain their participation every two 
weeks for at least 12 months (mean ± SD = 10.00 
± 3.64). 
The study was approved by the ethics com-
mittee of the hospital. Moreover, written consent 
was obtained from all patients before their parti-
cipation in the study.
Diagnostic and treatment methods
The diagnosis of PAP was based on three 
criteria, which were different in each case, i.e. ra-
diographic findings on HRCT in some cases, patho-
logical/cytological outcomes and positive result of 
GM-CSF autoantibody [22] in others; but definitive 
diagnosis of PAP was confirmed by bronchoalveolar 
lavage or lung biopsy (transbronchial or open). 
All patients had been treated for TB about 
six months with isoniazid and rifampicin before 
conducting the first WLL. We made sure that all 
patients had been cured completely, not only of 
TB but also of other infections.
It was the first time that WLL, which is often 
chosen as the first option of PAP disease treatment 
[7], was performed in the Iranian population.
Whole lung lavage
The procedure was conducted by an expe-
rienced lavage team including an interventional 
pulmonologist, anesthesiologist, nurse and re-
spiratory therapist. WLL was carried out under 
general anesthesia. The lungs were ventilated 
with FiO2 of 1.0 for 15 minutes. Then degassing 
was performed at a rate of up to 125 ml/min for 
10–15 minutes. Warm saline (to 370C) flowed into 
the lung slowly. The filling continued up to the 
estimated functional residual capacity volume 
of the lung and then suction was done. Repe-
ated cycles of lung filling with warmed saline 
(500–1000 cc) continued for 2 minutes with chest 
percussion therapy. Lavages had been continued 
under control until the returned fluid was clear. 
Lavage is the main treatment of PAP. In our study, 
all patients received whole lung lavage as the 
treatment but we did not perform lavages of both 
lungs at the same time. The number of lavages 
varied from one to 12, basing on O2 saturation, 
medical state and CT findings of each patient. 
Bronchoalveolar lavage
BAL was performed in accordance with the 
standard protocol confirmed by the Department of 
Pulmonary Medicine. Through a two-way syringe, 
20 ml of sterile saline (0.9%) was inserted in the 
suction port, after that, the fluid was pulled back 
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Table 1.  Spirometry, arterial blood gases analyses, six-minute walking distance results before and after whole-lung  
lavages
Index Before treatment After treatment p-value
DLCO% 52.66 ± 13.41 63.34 ± 13.30 < 0.0001*
FEV1% 58.46 ±  9.60 68.20 ± 7.410 < 0.0001*
FVC% 59.28 ±  8.70 68.70 ± 8.50 < 0.0001*
O2 Sat% 81.30 ± 3.70 92.00 ± 2.30 < 0.0001*
O2 Pressure, mm Hg 58.30 ± 2.20 70.30 ± 7.00 < 0.0001*
CO2 Pressure, mm Hg 35.40 ± 2.30 40.52 ± 1.15 < 0.0001*
6MWD, meter 381.40 ± 61.90 476.80 ± 39.50 < 0.0001*
Data are presented as the mean ± SD for 45 patients; asterisk indicates significant (p < 0.05); DLCO — diffusing capacity of the lungs for carbon monoxide; FEV1 — 
forced expiratory volume in one second; FVC — forced vital capacity; O2 sat — oxygen saturation; 6MWD — 6 min walking distance
immediately by the use of 50–100 mm Hg negative 
pressure suction. The lavage and suction process 
was repeated up to four times. The collected fluid 
was clinically analyzed. 
Transbronchial lung biopsy
TBLB was performed by experienced pul-
monologist under conscious sedation. Six-eight 
tissue specimens were obtained from the right 
middle lobe and lower lobe of all cases with 
standard biopsy forceps (sample size ~ 3 mm).
Data collection 
Demographic and historical data, signs and 
symptoms, radiologic features, diagnostic moda-
lities and the number of conducted WLL were 
recorded. Efficiency of WLL was assessed by 
comparing spirometric parameters, arterial blood 
gas analysis (PaO2, PaCO2 and O2 saturation) and 
six-minute walk test (6MWT). The lung function 
tests were performed before and after all the lava-
ges, and the data, which are presented in Table 1, 
were collected before performing WLL and after 
all the lavages.
Statistical analysis
Variables were reported as frequency and 
percentage for qualitative data, and the quan-
titative variables were described as means ± 
standard deviation. The normality distribution 
was performed using the Kolmogorov Smirnov 
(KS) test. Spirometry, arterial blood gas analysis, 
six-minute walk test results before and after 
whole-lung lavages were compared using T-test 
for parametric data and the Mann-Whitney U test 
for nonparametric data.
Demographic data, clinical manifestation 
including symptoms, diagnostic methods, co-
morbid diseases, spirometry and 6MWT result 
and arterial blood gas analysis were compared 
between “the treatment failure group” and 
“treatment responders group” using chi-square 
test for qualitative data and parametric paired 
t-test and nonparametric Mann Whitney U test 
for continuous variables. Logistic regression 
was applied for predicting the treatment failure 
based on some predictor variables. Data were 
analyzed by using statistical software (SPSS 
22) and the level of statistical significance was 
set at p < 0.05.
Results
Forty-five patients who were diagnosed with 
PAP between March 2004 and March 2015 and 
had regular follow-ups were included in the 
study. 
Results before and after WLL are shown in 
Table 1. FVC%, FEV1, DLCO%,O2sat, O2 pressure, 
CO2 pressure and 6MWD increased significantly 
after WWL.
Demographic and historical data: The study 
group consisted of 21 (46.7%) females and 24 
(53.3%) males. Beside three cases under 14 years 
of age who were classified as the “pediatric gro-
up”, the mean age at diagnosis was 30.33±14.56 
years. Male to female ratio was 1.1 among adults 
(Table 2). Active pulmonary tuberculosis and 
hypothyroidism were identified as comorbidities. 
The patients had been investigated regarding 
occupational exposure. The types of dusts the 
patients had been exposed to included as follows: 
silica, aluminum oxide and a variety of dusts and 
fumes (Table 2). 
Clinical manifestation: Dyspnea was the 
most common symptom found among the pa-
tients; cough was the second most frequent ma-
Advances in Respiratory Medicine 2018, vol. 86, no. 1, pages 7–12 
10 www.journals.viamedica.pl










4 (8.8%)Non massive hemoptysis
0Sweats
32 (71.1%)Bronchoalveolar lavage stainingDiagnostic methods
13 (28.8%)Transbronchial lung biopsy





Environmental risk factor exposure





Occupational Dust Exposure 2 (4.8%)Aluminum oxide
1(2.4%)Fumes
nifestation, non-massive hemoptysis was reported 
in less than 10% of the patients (Table 2).
Diagnostic method: BAL and TBLB were used 
as a diagnostic tool in more than 70% of patients. 
Open lung biopsy was required only in cases in 
whom BAL or TBLB were non-diagnostic.
The median time from diagnosis of PAP to 
performing WLL was 3-24 months in both pedia-
tric and adult groups. Beside the pediatric group 
in which the time between the symptoms onset 
and diagnosis was under 6 months, the majority 
(95%) of adults were diagnosed with PAP between 
3-24 months from the first manifestation of symp-
toms. All patients had been hospitalized between 
1-4 weeks in the hospital. 
Treatment method: All patients received 
WLL as the treatment. The number of lavages was 
different in each case — from one to 12 lavages 
(mean ± SD for WLL: 6.91 ± 3.31), according 
to the patient’s state and O2 saturation. Mean 
spirometric, arterial blood gas parameters and 
the results of 6MWD improved significantly after 
lavages (p-value < 0.0001) (Table 1).
Disease course: All patients had follow-up 
at least 12 months after diagnosis (mean ± SD: 
10.00 ± 3.64). Three pediatric patients died 
during this period as a result of respiratory 
failure. One adult who has presented with he-
moptysis and dyspnea died within five months 
after WLL, and seven other patients (15.6%) de-
veloped respiratory failure during the follow-up 
period. According to these results, relapses were 
seen in 11 patients (24.4%). Other patients did 
not show any relapses or adverse effects during 
observation time.
The patients who died or developed respira-
tory failure (11 patients, 24.4%) were categorized 
into the “treatment failure group” while the re-
maining 34 patients were classified as “treatment 
responders”. Demographic, historical and clinical 
characteristics of treatment failure and treatment 
responders groups were compared.
After analysis, the four following variables 
were shown to be different between the two 
groups: 1 — hemoptysis, 2 — concomitant tu-
berculosis, 3 — six-minute walk test (6MWT) 
distances, 4 — oxygen saturation after lavages. 
Logistic regression analysis was conducted 
afterwards, considering these variables, which 
were shown to be different between the two 
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groups, in order to determine independent 
predictors of treatment failure. Among the 
four variables, i.e. hemoptysis, concomitant 
tuberculosis, six-minute walk test distance and 
oxygen saturation after lavages, hemoptysis 
was the only variable capable of significantly 
predicting treatment failure (p-value = 0.03 
odds ratio: 23).
No significant relationship was observed 
between the number of lavages and patients’ 
outcome using the Mann Whitney U test (p-value 
= 0.9). No significant difference was observed 
between smoking cigarette and the number of 
performed lavages using the Pearson’s correlation 
coefficient (r). P < 0.05 was considered statisti-
cally significant (r = 0.207; p = 0.177). 
CT findings: The “crazy-paving” pattern (gro-
und glass opacity [GGO] and reticular bilateral 
upper zone) was the most common finding of 
computed tomography (CT) — it was seen in 28 
patients (62.2%). Bilateral upper zone GGO was 
the second common feature which was found in 
the CT scans of 12 patients (26.7%). Nodular or 
reticular radiographic features in the lower zone 
were totally seen in five patients (11.11%).
Discussion
Although some studies from different co-
untries have described demographic features, 
clinical characteristics, diagnostic modalities and 
treatment outcomes of PAP patients worldwide 
[3, 14, 15, 18], this study is the first report on the 
Iranian population.
WLL was found as the sufficient treatment 
for PAP patients due to significant improvement 
of spirometric parameters, oxygen saturation, 
arterial blood gas analysis and 6MWD after WLL 
(p-value < 0.0001). This confirmed previous 
findings indicating that WLL is the sufficient 
treatment for PAP [3, 11, 13–15]. 
The sufficiency of BAL and TBLB as diagno-
stic methods were consistent with the results of 
Inoue et al., Xu et al. and Bonella et al. studies 
[13–15] but were different from Seymur’s meta
-analysis [3].
Mean age at diagnosis among adult PAP 
patients was lower in the Iranian population in 
comparison to the Japanese [15], German [13], 
Chinese [14] and Korean populations [17], but 
it was comparable to the Israeli population [18]. 
This could raise the possibility that geographic or 
ethnic factors play a role in determining the ma-
nifestation age of PAP. This probability requires 
further investigation. 
Regarding gender distribution, there was 
no predominance of males, and male to female 
ratio was 1.1, similarly to studies conducted in 
Germany and Israel [18, 23], and in contrast to 
the majority of previous studies that reported 
a 2-fold predominance of males [3, 14, 15].
Nine patients (20%) had history of dust expo-
sure similar to the report in the Inoue’s study [15] 
but lower than it was documented in the paper 
by Bonella et al. [13]. An overall number of 11 
patients (24.4%) had an underlying comorbidity 
(active tuberculosis) or dust exposure. Those 
patients who had active tuberculosis or dust 
exposure might have had secondary PAP, howe-
ver, we could not definitely distinguish primary 
from secondary PAP due to lack of access to 
laboratory facilities for measuring anti-GM-CSF 
autoantibody. This is one of the limitations of the 
present study.
The study also analyzed different variables 
in order to investigate their contribution to treat-
ment failure. The four variables, i.e. hemoptysis, 
concomitant tuberculosis, 6MWD and oxygen sa-
turation after lavages were significantly different 
in the treatment failure and treatment responder 
groups. Given the fact that tuberculosis — the 
disease which is a frequent cause of hemopty-
sis — is endemic to our country — and since 
hemoptysis has been an independent predictor 
of treatment failure in our patients, considering 
concomitant tuberculosis in PAP patients and 
proper treatment of tuberculosis may improve 
outcome in PAP patients. Larger studies are 
warranted to investigate the exact relationship 
between tuberculosis treatment and prognosis 
of PAP patients.
Lack of significant association between smo-
king cigarette and the number of performed 
lavages is in contrast to the results obtained by 
Bonella et al. [13], according to whom, smokers 
needed twice as many lavages as non-smokers.
To the best of our knowledge, no study has 
reported the status of passive smoking in PAP 
patients. Although a noticeable number of passive 
smokers had been seen among patients, a true 
causative relationship between PAP and passive 
smoking is not clear yet. Therefore, more inve-
stigation is needed in this area.
Conclusion
To conclude, regarding the significant impro-
vement in spirometry result, ABG gas analysis 
and 6MWD after all lavages, our study revealed 
sufficiency of WLL as the PAP patients’ treatment. 
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Hemoptysis was the only independent factor 
that could predict treatment failure, therefore 
in Iran, where tuberculosis is endemic, proper 
treatment of tuberculosis may improve outcome 
in PAP patients.
Acknowledgements
The authors wish to thank all the PAP pa-
tients and all laboratory specialists who helped 
them to get results of better quality.
The authors declare no conflict of interest.
References: 
1. Rosen SH, Castelman B, Liebow AA. Pulmonary alveolar prote-
inosis. N Engl J Med. 1958; 258(23): 1123–1142, doi: 10.1056/
NEJM195806052582301, indexed in Pubmed: 13552931.
2. Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar prote-
inosis. N Engl J Med. 2003; 349(26): 2527–2539, doi: 10.1056/
NEJMra023226, indexed in Pubmed: 14695413.
3. Seymour JF, Presneill JJ, Presneill JJ, et al. Attenuated hema-
topoietic response to granulocyte-macrophage colony-stimu-
lating factor in patients with acquired pulmonary alveolar 
proteinosis. Blood. 1998; 92(8): 2657–2667, indexed in Pub-
med: 9763547.
4. Whitsett JA, Wert SE, Weaver TE. Alveolar surfactant ho-
meostasis and the pathogenesis of pulmonary disease. 
Annu Rev Med. 2010; 61: 105–119, doi: 10.1146/annurev.
med.60.041807.123500, indexed in Pubmed: 19824815.
5. Inoue Y, Trapnell BC, Tazawa R, et al. Japanese Center of 
the Rare Lung Diseases Consortium. Characteristics of a lar-
ge cohort of patients with autoimmune pulmonary alveolar 
proteinosis in Japan. Am J Respir Crit Care Med. 2008; 177(7): 
752–762, doi: 10.1164/rccm.200708-1271OC, indexed in Pub-
med: 18202348.
6. Kitamura T, Tanaka N, Watanabe J, et al. Idiopathic pulmonary 
alveolar proteinosis as an autoimmune disease with neutrali-
zing antibody against granulocyte/macrophage colony-stimu-
lating factor. J Exp Med. 1999; 190(6): 875–880, indexed in 
Pubmed: 10499925.
7. Michaud G, Reddy C, Ernst A. Whole-lung lavage for pulmo-
nary alveolar proteinosis. Chest. 2009; 136(6): 1678–1681, doi: 
10.1378/chest.09-2295, indexed in Pubmed: 19995769.
8. Ioachimescu OC, Kavuru MS. Pulmonary alveolar pro-
teinosis. Chron Respir Dis. 2006; 3(3): 149–159, doi: 
10.1191/1479972306cd101rs, indexed in Pubmed: 16916009.
9. Gay P, Wallaert B, Nowak S, et al. Groupe d’’Endoscopie Tho-
racique de Langue Française. Efficacy of Whole-Lung Lavage 
in Pulmonary Alveolar Proteinosis: A Multicenter Interna-
tional Study of GELF. Respiration. 2017; 93(3): 198–206, doi: 
10.1159/000455179, indexed in Pubmed: 28118623.
10. Beccaria M, Luisetti M, Rodi G, et al. Long-term durable benefit 
after whole lung lavage in pulmonary alveolar proteinosis. Eur 
Respir J. 2004; 23(4): 526–531, indexed in Pubmed: 15083749.
11. Campo I, Luisetti M, Griese M, et al. WLL International Study 
Group. Whole lung lavage therapy for pulmonary alveolar pro-
teinosis: a global survey of current practices and procedures. 
Orphanet J Rare Dis. 2016; 11(1): 115, doi: 10.1186/s13023-
016-0497-9, indexed in Pubmed: 27577926.
12. Awab A, Khan MS, Youness HA. Whole lung lavage — tech-
nical details, challenges and management of complica-
tions. J Thorac Dis. 2017; 9(6): 1697–1706, doi: 10.21037/
jtd.2017.04.10, indexed in Pubmed: 28740686.
13. Bonella F, Bauer PC, Griese M, et al. Pulmonary alveolar pro-
teinosis: new insights from a single-center cohort of 70 pa-
tients. Respir Med. 2011; 105(12): 1908–1916, doi: 10.1016/j.
rmed.2011.08.018, indexed in Pubmed: 21900000.
14. Xu Z, Jing J, Wang H, et al. Pulmonary alveolar proteinosis in 
China: a systematic review of 241 cases. Respirology. 2009; 
14(5): 761–766, doi: 10.1111/j.1440-1843.2009.01539.x, in-
dexed in Pubmed: 19476601.
15. Inoue Y, Nakata K, Arai T, et al. Epidemiological and clini-
cal features of idiopathic pulmonary alveolar proteinosis in 
Japan. Respirology. 2006; 11 Suppl: S55–S60, doi: 10.1111/j.
1440-1843.2006.00810.x, indexed in Pubmed: 16423273.
16. Prakash UB, Barham SS, Carpenter HA, et al. Pulmonary 
alveolar phospholipoproteinosis: experience with 34 cases 
and a review. Mayo Clin Proc. 1987; 62(6): 499–518, indexed 
in Pubmed: 3553760.
17. Byun MK, Kim DS, Kim YW, et al. Clinical features and out-
comes of idiopathic pulmonary alveolar proteinosis in Kore-
an population. J Korean Med Sci. 2010; 25(3): 393–398, doi: 
10.3346/jkms.2010.25.3.393, indexed in Pubmed: 20191038.
18. Ben-Dov I, Kishinevski Y, Roznman J, et al. Pulmonary alveolar 
proteinosis in Israel: ethnic clustering. Isr Med Assoc J. 1999; 
1(2): 75–78, indexed in Pubmed: 10731299.
19. Parsa T, Tajbakhsh A, Ahmadi ZH. Management of Alveolar 
Proteinosis by Bronchopulmonary lavage under Extra Corpo-
real Membrane Oxygenation (ECMO). Journal of Cellular & 
Molecular Anesthesia. 2015; 1(1): 40–42.
20. Radpay B, Parsa T, Khalilzadeh S. Whole lung lavage under 
general anesthesia in a child with pulmonary alveolar prote-
inosis (A case report). Tanaffos. 2004; 3(9): 61–67.
21. Radpay B, Parsa T, Dabir S. Whole lung lavage of nine children with 
pulmonary alveolar proteinosis: experience in a tertiary lung center. 
Iran J Pediatr. 2013; 23(1): 95–99, indexed in Pubmed: 23550265.
22. Bradley B, Branley HM, Egan JJ, et al. British Thoracic Society In-
terstitial Lung Disease Guideline Group, British Thoracic Society 
Standards of Care Committee, Thoracic Society of Australia, New 
Zealand Thoracic Society, Irish Thoracic Society. Interstitial lung 
disease guideline: the British Thoracic Society in collaboration 
with the Thoracic Society of Australia and New Zealand and 
the Irish Thoracic Society. Thorax. 2008; 63 Suppl 5: v1–58, doi: 
10.1136/thx.2008.101691, indexed in Pubmed: 18757459.
23. Bonella F, Bauer PC, Griese M, et al. Pulmonary alveolar pro-
teinosis: new insights from a single-center cohort of 70 pa-
tients. Respir Med. 2011; 105(12): 1908–1916, doi: 10.1016/j.
rmed.2011.08.018, indexed in Pubmed: 21900000.
